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The Extracellular RNA (exRNA) Communication Consortium was launched by the National Institutes of Health
to focus on the extent to which RNA might function in a non-cell-autonomous manner. With the availability
of increasingly sensitive tools, small amounts of RNA can be detected in serum, plasma, and other bodily fluids.
The exact mechanism(s) by which RNA can be secreted from cells and the mechanisms for the delivery and uptake
by recipient cells remain to be determined. This review will summarize current knowledge about the biogenesis
and delivery of exRNA and outline projects seeking to understand the functional impact of exRNA.
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T
he RNA world and analysis of modern roles for
RNA have produced a number of surprises,
notably catalytic RNA, the discovery of introns,
the prevalence of alternative splicing to generate protein
diversity, RNA interference, and riboswitches that link
metabolism with gene expression (1). Recent discoveries
showing the extent of transcription within eukaryotic
genomes have demonstrated that many RNA species exist
in cells, but the exact function of most of these transcripts
remains unknown (24). Many of these RNAs are non-
coding. The best-characterized non-coding RNAs are
small microRNAs (miRNAs), but many other non-
coding RNAs have been identified that appear to play
roles in genome defense or chromatin organization (59).
An underlying assumption for many years has been that
RNA function is cell autonomous, especially given the

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levels of RNAse in extracellular fluids and plasma that
function to destroy foreign RNAs, most commonly viral
RNA. However, new highly sensitive tools have enabled
the discovery of extracellular host RNA in both the
bloodstream and multiple body fluids (10). How these
RNAs are exported from donor cells, how they are taken
up by and/or targeted to specific recipient cells, and how
they are released to function inside recipient cells remain
mostly unanswered questions. To address these questions,
the National Institutes of Health Common Fund laun-
ched a new program, the Extracellular RNA (exRNA)
Communication Consortium. This review will summarize
the projects focusing on biogenesis and delivery mecha-
nisms, and the function of exRNA.
RNA export
To avoid degradation, it is thought that most exRNAs are
either encased within membranous vesicles or are tightly
associated with proteins and/or lipids. Extracellular vesi-
cles (EV) include exosomes (40100 nm) and larger
microvesicles but could conceivably also include apoptotic
vesicles released upon cell death (11,12) (Fig. 1). Multiple
studies have focused on exosomes as carriers of RNA, in
part due to RNA sequencing/microarray studies per-
formed from purified exosomes (1315), as well as loca-
lization of miRNA effector complexes associated with
multivesicular bodies (MVBs) (16,17). Exosomes are
endosomally derived vesicles that form by invagination
into MVBs and contain proteins involved in endosomal
transport and fusion (18). Normally, MVBs are targeted to
lysosomes for degradation, but they can also fuse with the
plasma membrane, thereby releasing exosomes into the
extracellular space. Deposition of some, but not all, RNAs
into exosomes might be explained by import into MVBs
during the intraluminal vesiculation process. This explains
the presence of miRNAs in exosomes since the RISC
machinery that processes miRNAs has been localized to
the surface of MVBs (16,17). Exosomes that originate
from MVBs and contain miRNAs may not necessarily
require ESCRTS for assembly (19,20). Inhibition of
ceramide synthesis by blocking neutral sphingomyelinases
can cause a decrease in exosome release and secreted
miRNAs, although this may be cell specific (2124). How
longer RNAs, particularly mRNAs or long non-coding
RNAs are targeted for export into exosomes or micro-
vesicles is not clear (15,25,26). From microarrays and
RNA sequencing experiments, numerous sequences are
detected from multiple classes of RNA, including rRNAs
and mRNAs, but the abundance and activity of full-length
mRNA remain uncertain (13,15,27,28). Similarly, it is not
known if there is a size threshold for long non-coding
RNAs. For these reasons, most work has focused on
miRNA deposition into exosomes.
miRNAs can also be found in extracellular fluids in
complex with either Argonaute proteins (29) or as part of
lipoprotein particles, mostly HDL (30). Quantitative
analysis of miRNA content in exosomes has suggested
that individual exosomes contain vanishingly small num-
bers of miRNA molecules, far lower than would be
expected if exported miRNAs function stoichiometrically
in recipient cells (31). While somewhat controversial, one
explanation to account for these results is that different
subclasses of exosomes exist, only some of which contain
miRNAs or other RNAs. A second possibility is that
functional miRNA is transported via Ago2 complexes or
as part of HDL particles (Fig. 1). Stoichiometric concerns
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Fig. 1. Biogenesis and uptake of exRNA. Endocytosis is commonly mediated via clathrin-coated pits (1) after which endocytic vesicles
progress from early (2) to late endosomes, also referred to as multivesicular bodies (MVBs). MVBs often fuse with lysosomes for degradation
(4) but can also fuse with the plasma membrane (5) thereby releasing exosomes (40100 nm) to the extracellular space. Microvesicles are
larger fragments of plasma membrane that are shed from almost all cells (6). Extracellular RNA (exRNA) can be detected in exosomes and
microvesicles, associated with proteins (7), or as part of lipoprotein particles, particularly HDL. exRNA released from secreting cells can be
taken up by recipient cells through receptor-mediated endocytosis (8), by fusion of membranes, or by uptake of RNAprotein complexes or
lipoproteins. Although the exact mechanisms remain unclear, exRNA is released inside recipient cells (9) to effect changes in gene expression.
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might be sidestepped in these latter cases but the issue
remains as to exactly how miRNAs are packaged into
HDL particles or how Ago2 complexes are released from
cells. In addition, it is not clear how such miRNAs
reassemble into functional RNA Induced Silencing Com-
plexes upon import into recipient cells. A third explanation
is that exosomes and exosomal cargo purified from fluids
or cell culture medium might not necessarily reflect the
extent of continuous transfer that might be occurring
between directly adjacent cells.
Experiments comparing cellular miRNA expression
profiles to exosomal or HDL profiles are underway. The
weight of evidence thus far favours the idea that the 2
profiles are distinct, suggesting that there are likely to
be signals that preferentially export specific miRNAs
(11,15,27,30,3235).
Delivery of exRNA
After export from donor cells, proposed mechanisms for
how RNAs are delivered to recipient cells depend on
whether they are part of exosomes (or other vesicles),
HDL, or Ago2 complexes (Fig. 1). Receptor-mediated
uptake would be expected for HDL-associated miRNAs
(scavenger receptor class B type 1) (30) and exosomes by
a variety of membrane receptors matched to exosomal
ligands (23,27,3638). It is not clear how recipient cells
would take up Ago2-miRNA complexes. Receptors exist
to transfer double-stranded RNA in Caenorhabditis
elegans, mammals (39), flies (40), and plants (41). It will
be interesting to determine what role such receptors/
pathways play in mediating the uptake of exRNA.
Functional transfer of exRNA
The greatest short-term impact of the discovery of exRNA
might be the identification of biomarkers of disease because
it does not involve functional transfer of RNA to recipient
cells (42). However, if RNAs are specifically targeted for
export and cells use receptor-mediated mechanisms to
uptake specific particles or complexes, a logical extension is
that gene expression patterns in recipient cells should be
altered. Exosomes can mediate functional effects in recipient
cells, but whether RNA is essential and the extent to
which gene expression can be altered remain to be precisely
determined. In models of colorectal cancer, exosomes
released from KRAS mutant cell lines can increase the
invasiveness of recipient cells, but this could be due to transfer
of mutant KRAS via EGFR ligand signalling or other
protein-mediated mechanisms (37,43). Among other exam-
ples, exosomal transfer from stromal to breast cancer
cells can alter radiation sensitivity (44), exosomes released
from cardiosphere-derived cells can promote proliferation of
cardiomyocytes (45), glioblastoma microvesicle transfer
can promote tumour growth (15), EVs can transfer
between endothelial cells and smooth muscle cells for
atheroprotective communication (46), exosomal transfer
of miR-146a from endothelial cells to cardiomyocytes can
alter metabolism (47), and exosomal transfer of miRNAs
and miRNA processing machinery can occur between
tumorigenic and non-tumorigenic cells (48). In all these
cases, exRNA transfer may play a significant role, but the
exact extent to which the effects are RNA mediated
remains to be determined. For RNA transfer, exosomes
can indeed transfer miRNAs but the experiments to
demonstrate such transfer often involve culturing recipi-
ent cells with largely non-physiological concentrations of
exosomes (15,27,36,49,50). To attempt to recapitulate
more physiological conditions, co-culture experiments,
Transwell experiments, systemic injection of exosomes,
implantation of Matrigel plugs containing exosomes,
and xenograft experiments have all shown that exosomal
contents can be transferred to some extent to recipient
cells (23,44,45,4951).
While many of the above experiments show that exRNA
can be delivered, it remains unclear how these RNAs are
released for functional activity upon entry into recipient
cells. As discussed above, miRNA function is particularly
challenging since stoichiometric delivery would seem to be
required to effect significant changes in gene expression
(31). One possibility is that delivery of exRNAs might
induce changes reminiscent of immune activation. miRNAs
are ligands of Toll-like receptors and as such could con-
ceivably mediate their effects by activating downstream
signalling cascades (52,53). Antiviral immunity is often
conferred by recognition of RNAs bearing 5? dispho-
sphates by Rig-1 (54). Interestingly, transfer of RNA from
stromal to breast cancer cells within exosomes stimulates
RIG-1 to activate STAT1 signalling (44).
In summary, with the availability of increasingly sensi-
tive tools, there is little doubt that exRNAs exist. However,
mechanistic understanding of how RNAs are released
from cells and how or whether they can be specifically
targeted to recipient cells to alter gene expression patterns
remains mostly unknown. To tackle these questions, 5
groups within the exRNA Communication Consortium
are studying the biogenesis of exRNA.
exRNA released by glioblastoma alters brain
microenvironment (Dr. Xandra Breakefield, Principal
Investigator, Harvard Medical School,
Massachusetts General Hospital)
The unifying theme of the Breakefield group focuses on
biogenesis and release of exRNA by glioblastoma (GBM)
and modes of uptake and functional consequences in
normal cells in the brain microenvironment. Our over-
riding hypothesis is that GBM release exRNAs that are
taken up by normal cells in their environs and change their
gene expression, which, in turn, determines the malig-
nant potential of the tumour and host response. GBMs
represent one of the most common and aggressive brain
tumours in humans, with time from diagnosis to death
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being about 1 year and no effective treatments available.
Since GBMs are rarely metastatic, they provide a system to
study the effects of exRNA in a confined environment with
relatively few principal normal cell types in the immediate
vicinity. Key questions:
a. Elucidate basic molecular and cellular mechanisms
of exRNA biogenesis in GBM cells, exRNA uptake
and function in normal brain cells, using existing and
emerging technologies such as RNA interference and
gene editing to manipulate these processes.
b. Characterize the exRNA content and intracellular
RNA content of human GBM cells, as well as the intra-
cellular RNA content of normal brain cells, and evalu-
ate functional transfer of exRNAs from GBM cells to
brain cells in culture and in GBM mouse brain models.
c. Evaluate transfer and fate of exRNA in brain cells,
including visualizing RNA transfer in EVs, monitor-
ing mRNA translation and miRNA functions, deter-
mining possible genomic integration of transposable
elements and oncogenes, and evaluating effects of non-
coding exRNAs on status of genome methylation.
d. Study dependence of exRNA cargo composition,
formation, and release dynamics as a function of
GBM genotype, including activation of EGFR and
PDGFRa signalling pathways, which are the 2 most
common genetic events in human GBM tumours, as
well as changes in GBM exRNA in response to
radiation and drug treatment.
e. Develop and engineer regulators of exRNA release
and uptake and tailor fluorescent and other visual
labels, vectors, mouse models and reagents for broad
applications in monitoring exRNA release, uptake
and function in culture and in vivo.
In vivo regulated release and function of extracellular
small RNAs (Dr. Robert Blelloch, Principal
Investigator, University of California, San Francisco)
The Blelloch group focuses on how different stimuli influ-
ence the differential release of exRNAs. They address this
question in several different contexts including prostate and
liver cancer, immune cell activation, and olfactory sensory
input. All these studies use systems that enable fine temporal
control of the stimuli, enabling dissection of the sequence of
events that occur from the time of the stimulus to the exRNA
release. Furthermore, they hypothesize that exRNA release
may not only function by altering neighbouring cells, but also
by rapidly changing the intracellular content of exRNAs in
the source cell. On-going studies are focused on 2 areas:
a. Strong evidence exists that exRNAs and in particular,
extracellular miRNAs, can act as biomarkers of
cancer. However, little work has been done to find a
direct link between molecular changes, genetic or
epigenetic, in cancer cells and the release of miRNAs.
Members of our group have done extensive analysis of
intracellular changes in the miRNA population fol-
lowing different oncogenic stimuli in the context of
liver cells (55). We have also made the surprising
discovery that serum exRNAs associated with prostate
cancer can change during progression independent of
changes in the intracellular pool, suggesting regulative
secretion or alternative sources of the miRNAs (56).
Our group is using prostate cancer and liver cancer
models to build on these findings and to understand
how specific signalling pathways are altering both
intracellular and exRNA populations.
b. Signal-induced extracellular miRNA release occurs in
healthy cells of the immune system. Many of the sig-
nalling networks involved in oncogenesis also mediate
immune cell ‘‘activation,’’ inducing growth, prolifera-
tion, and differentiation into effectors of immunity.
Activated dendritic cells, macrophages, and T cells are
all potent sources of exosomes (36,5759). Indeed, the
immunological properties of EVs, particularly exo-
somes, have long been studied (60). The discovery of
their RNA cargo may shed new light on these proper-
ties. In addition, T cells and dendritic cells form stable
‘‘immune synapses’’ that direct cell surface molecules,
secreted cytokines, and other mediators of intercellular
communication towards one another. These close
interactions may facilitate sufficient exchange of ex-
miRNAs to affect gene expression in recipient cells
(23). Ex-miRNAs have also been implicated in com-
munication among different subsets of T cells (61,62),
or dendritic cells (36), and between macrophages and
cancer cells (57). Even if ex-miRNAs do not mean-
ingfully alter the fate or function of recipient cells in a
physiological context, their release very likely affects
the source cells that jettison their miRNAs. For
example, T-cell activation induces rapid remodelling
of the cellular miRNA repertoire through a combina-
tion of miRISC degradation and induced ex-miRNA
release (58,63). Cellular miRNA ‘‘disposal’’ by extra-
cellular release has also been linked to gain of metas-
tatic behaviour in bladder cancer (64). Thus, common
principles and mechanisms may govern ex-miRNA
release and function in immune cells and cancer cells.
c. Neurons, like immune cells, may dynamically redefine
their cellular function by jettisoning repressive RNA
in response to stimulation. Expelling repressive RNA
from locally stimulated synapses  as shown in
Goldie et al. (65)  could serve a dual purpose: to
both increase local translation and promote the
synapse specific strengthening required for long-term
memory formation (66) as well as to communicate
with neighbouring cells. Evidence that neurons se-
crete exosome-like vesicles comes from extensive
purification and electron microscopic analysis of
supernatants from cultured neural stem cells, cultured
James G. Patton et al.
4
(page number not for citation purpose)
Citation: Journal of Extracellular Vesicles 2015, 4: 27494 - http://dx.doi.org/10.3402/jev.v4.27494
cortical neurons, and even cultured male C. elegans
(56,67,68). Though the contents of the male specific
vesicles promote mating behaviour, what the content
of most neuronal exosomes does is still an active area
of research. What we do know is that the protein and
RNA contents change with neural excitation, differ-
entiation, and the state of the circuit (online resour-
ces Exocarta and Vesiclepedia (69)). As cancer cells
may utilize miRNAs to create a hospitable tumour
environment, neurons may use exRNA to enlist the
function of glial support cells to provide an environ-
ment that is compatible with neuronal activity. Morel
et al. (70) showed that vesicles containing miR-124a
and secreted from stimulated neurons are taken up by
astrocytes. Within astrocytes, miR-124a indirectly
upregulates the glutamate transporter GLT1 thereby
limiting glutamate-induced excitotoxicity of neurons
by sopping up excess glutamate. The evidence that
environmental stimulation increases the expression of
regulatory RNAs in C. elegans sensory neurons (71)
coupled with the potential for spread of the RNA
signal throughout the organism (72) may allow
exRNAs to communicate from one cell to the next
or even from one animal to the next (73).
Genetic models for exRNA communication (Dr.
Michael McManus, Principal Investigator, University
of California, San Francisco)
The McManus group seeks to develop a panel of novel
genetic and cellular models to clarify and rationalize the
mechanisms of exRNA biogenesis, distribution, uptake,
and function in vivo.
a. Development of a highly robust ‘‘pOSI-sensor’’
technology to report on exRNA uptake and activity
in cells. In contrast to negative sensors, such sensors
allow for the detection of exRNA transport in single
cells. This feature is important as it is expected that
within tissues, exRNA mode of action will be tightly
regulated, notably by cell differentiation, external
stimuli, and/or by the expression of specific licensing
factors. By combining the use of miRNA pOSI
sensors with corresponding miRNA knockout mice,
these experiments will be able to exclude the con-
tribution of endogenous miRNA in recipient cells.
b. Detect local or systemic functional exRNA transfer
events in diverse normal or pathological situations
such as those occurring in tumourhost communica-
tion, secreting epithelia and muscle development, and
digestion of breast milk or dietary plant-derived RNAs.
c. Systematically investigate cell-to-cell miRNA transfer
in a wide array of tissues using a mouse chimera
approach.
d. Determine the role of mammalian homologs of C.
elegans sid-1 RNA transporter (SidT1 and SidT2).
RNA transport defects in SidT1/2 mice will be used
to identify exRNAs that require these proteins for
their accumulation (or depletion) in cell culture
medium and body fluids, and will notably adapt
RNA-tagging and pOSI-sensor strategies to effi-
ciently detect their functional transfer.
e. Investigate the mechanisms of Argonaute release in
the extracellular space. Association of Argonaute
proteins with the endomembrane system is clearly
important for the activity and recycling of small RNAs
in cells but its impact on the extracellular release of
Argonaute remains unclear. We have developed a
unique cellular system allowing us to manipulate the
association of Argonautes to a diverse array of
endomembranes, which will allow us to identify key
cellular compartments supporting extracellular Argo-
naute accumulation and also identification of cellular
co-factors involved in this process. Lastly, we are
investigating the behaviour and possible uptake of
extracellular Argonautes in vivo using a combination
of transgenic and knockout animals.
Definition of serum ribonucleoprotein composition
and its regulation and function (Dr. Thomas Tuschl,
Principal Investigator, Rockefeller University)
exRNA from pathogens plays a key role as an activator
of innate immunity in mammals. However, the presence
of host exRNA in serum and other body fluids chal-
lenges current models of RNA-based immune recogni-
tion. To understand its basis of specificity, it is important
to catalogue host exRNAs and their associated proteins
in serum, investigate mechanisms leading to circulat-
ing ribonucleoprotein (RNP) homeostasis, and identify
protein factors contributing to cellular RNA release.
Genetic alterations in RNA targets or interacting pro-
teins may contribute to imbalances in normal versus
stress-triggered release of RNPs and push adaptive long-
term pathogen-directed immunity towards autoimmunity.
exRNAs may also play a broader role in extracellular
signalling similar to peptide hormones. Specific aims are
as follows:
a. Catalogue and quantify all classes of exRNAs in
human serum from normal subjects using RNAseq
approaches and examine normal variability of circu-
lating RNA profiles within an individual and between
individuals, considering the influence of gender, age,
race, and disease.
b. Determine exRNA composition in patients suffering
from systemic lupus erythematosus (SLE), for whom
antibodies against different classes of RBPs is a
hallmark.
c. Develop a molecular and mechanistic understanding
of stress granule formation and RNA/RNP-mediated
innate immune responses. Identify the RNA targets
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and RNP structures of autoantigens in tRNA stress
responses, their turnover, and their immune receptors.
Secreted RNA during colorectal cancer progression:
biogenesis, function, and clinical markers (Dr. Robert
Coffey, Principal Investigator, Vanderbilt University)
Specific export of exRNAs is likely to be regulated by
cellular signalling. However, few studies have addressed
the regulatory mechanisms that govern packaging of
exRNAs into various carriers and their secretion from
cells. Following up on findings that KRAS mutations in
colorectal carcinoma affect the RNA and RNA-binding
protein content of exosomes, the Coffey group is focusing
on regulation of exRNA secretion by oncogenic signal-
ling in colon cancer. The hypothesis is that oncogenic
signalling is a key driver of exosomal RNA and protein
cargo selection. Based on this hypothesis, the major goals
of this project are as follows:
a. Determine how the profile of exosome-associated
circulating RNAs changes as a function of tumour
genotype and colorectal cancer progression.
b. Determine intracellular proteins that mediate RNA
trafficking into exosomes in vivo.
c. Identify modes of exRNA-associated exosome intra-
vasation in vivo.
d. Determine the export specificity and functional
activity of exosomal miRNAs.
e. Test the hypothesis that late endosomes are scaffold-
ing and export sites for secreted RNAs.
f. Test the hypothesis that generation of differential
subpopulations of exosomes controls RNA export.
g. Determine the extent to which lipoprotein particles
mediates exRNA communication.
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